| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JCB.10242 |
| P698 | PubMed publication ID | 12210731 |
| P2093 | author name string | Andreas Burchert | |
| Lorenz C Hofbauer | |||
| Michael Schoppet | |||
| Christian A Kühne | |||
| Andreas Zielke | |||
| Colin R Dunstan | |||
| Armin E Heufelder | |||
| Sibylle Kluger | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death | Q29620519 | ||
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | Q33823576 | ||
| Thyrocyte-interleukin-1 interactions | Q33926780 | ||
| Death of the autoimmune thyrocyte: is it pushed or does it jump? | Q34013447 | ||
| Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | Q34079327 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter | Q34567704 | ||
| Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. | Q36364198 | ||
| TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo | Q36375923 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion | Q40920742 | ||
| Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells | Q40927574 | ||
| TRAIL death pathway expression and induction in thyroid follicular cells | Q40937072 | ||
| Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines | Q41000781 | ||
| Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin | Q41024303 | ||
| Cytokines and Graves' disease | Q41734154 | ||
| Graves' disease. | Q54276950 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 642-650 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Journal of Cellular Biochemistry | Q6294917 |
| P1476 | title | Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland | |
| P478 | volume | 86 |
| Q46948232 | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients |
| Q40143945 | Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death |
| Q40191084 | Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells |
| Q35853271 | Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis |
| Q48191527 | RANKL/Osteoprotegerin System and Bone Turnover in Hashimoto Thyroiditis |
| Q64089021 | Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer |
| Q79184844 | TSH Is a Negative Regulator of Skeletal Remodeling |
| Q35140845 | The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis |
Search more.